INTRODUCTION
============

The incidence and prevalence of both type 1 diabetes (T1D) and type 2 diabetes (T2D) are increasing worldwide, and in both cases there is a very large unmet medical need for pediatric and adult patients in these populations. However, over the recent past, "the most impressive changes in treatment and preventive strategies have been focused on type 2 diabetes," leading to significantly more approved drug entities for T2D than for T1D \[[@r1]\]. T1D therapeutic development has attracted much less attention than T2D, not only because T2D is much more common, but also because the clinical and regulatory efficacy endpoints of T2D are better established, easier to affect, and more feasible to measure: a related 2015 review in this journal focused on development of T2D drugs \[[@r2]\]. However, because essentially no therapies other than insulin products have been approved for T1D, it can be argued that greater unmet therapeutic need is found among people with T1D that those with T2D. This review therefore focuses on drugs and biologics that are under development for T1D indications.

The review does not attempt to cover important progress that has been made with closed-loop insulin pumps (artificial pancreas) and encapsulated islets, either manufactured or animal-sourced. In addition advances in cell therapies are not presented. It also does not attempt to cover the wide range of approaches and large number of programs aimed at diabetic complications, *e.g.*, nephropathy, neuropathy, retinopathy, and foot ulcers.

Pathophysiology of Type 1 Diabetes and Opportunities for Therapeutic Intervention
---------------------------------------------------------------------------------

T1D arises from autoimmunity that has a strong but not completely defined genetic predisposition. As reflected in (Fig. **[1](#F1){ref-type="fig"}**) and in the review by Skyler and Ricordi \[[@r3]\], clinical onset of T1D is preceded by highly variable periods of latency and subclinical autoimmune β-cell injury. These periods also define potential points of therapeutic intervention (Fig. **[2](#F2){ref-type="fig"}**). Intervening progressively earlier than at T1D clinical onset is challenging, as exemplified by the landmark Diabetes Prevention Trial\--Type 1 (DPT-1) \[[@r4]\]. This trial evaluated small injected doses of insulin and continues to evaluate oral doses of insulin. Randomization of approximately 800 participants required screening of about 100,000 first- and second-degree relatives of T1D patients to find about 4,000 individuals with islet cell antibodies. From that total, participants for randomization were selected to have a projected 5-year risk of clinical T1D \>25% \[[@r4]\].

People at T1D risk by familial relationship to a diagnosed patient account for only about 15% of the total population that goes on to develop T1D. HLA genotyping could be used at birth to screen the general population, but this approach has relatively low predictive value and has not been implemented \[[@r5]\]. For now, intervention at the root autoimmune cause of T1D is largely confined to patients who have been very recently diagnosed with T1D. Though new onset patients can feasibly be recruited into clinical trials, demonstrating efficacy in these trials is much more challenging than is the case for T2D trials. In contrast to trials that evaluate glucose-lowering therapies and use HbA1c as the primary endpoint, trials aimed at T1D autoimmunity evaluate the treatment's effect on the decline in endogenous insulin secretion as reflected by stimulated C-peptide levels \[[@r6]\]. Because of the high variability in stimulated baseline C-peptide levels, these trials must be longer and larger than typical trials with HbA1c as the endpoint \[[@r7], [@r8]\].

The Unmet and Underestimated Need of T1D
----------------------------------------

In glaring contrast to the wide array of approved drugs for T2D, the only drugs approved for T1D are insulins and pramlintide: these are presented in Table **[1](#T1){ref-type="table"}**. Miller *et al*. \[[@r9]\] discussed the limitations of available treatments for T1D, noting the need for new therapies to improve outcomes in this disease across all age groups, and observed that "only a minority of children and adults with type 1 diabetes achieve HbA1c targets," an observation that Cefalu *et al*. \[[@r1]\] considered "a sobering reminder" of the need for better therapies to facilitate better outcomes.

Although the 2014 United States (US) Centers for Disease Control and Prevention (CDC) report states that T1D represents about 5% of total patients with diabetes \[[@r10]\], this population is sizable, roughly 1.5 million people in the US alone. Even the CDC report provided very little information about T1D, instead focusing on T2D, which is undeniably a public health crisis but not a reason to neglect a large unmet clinical need in T1D. The prevalence of T1D is likely higher than suggested by reports that depend on clinical diagnoses. It was found in the United Kingdom Prospective Diabetes Trial (UKPDS) that about 10% of patients presumed to have type 2 diabetes at diagnosis had evidence of islet autoimmunity in the form of circulating ICA or GAD antibodies, and the majority progressed to insulin dependence within 6 years \[[@r11]\]. This syndrome was originally referred to as latent autoimmune disease in adults (LADA), but more recently has been found to occur in younger people \[[@r12]\]. A view is emerging that LADA is not a distinct entity, but that LADA and childhood-onset T1D are opposing ends of the same continuum of autoimmune diabetes \[[@r13]\]. The wider understanding of autoimmune diabetes leads to the conclusion that a substantially larger population has a form of T1D than is generally recognized. This concept also suggests a wider window of opportunity for interventions that prevent T1D or reduce the progression towards T1D.

The specific risk of greatest concern to people with T1D, which can be viewed as the basis of highest unmet need, is the risk of severe hypoglycemia that results from total dependence on injected insulin therapy \[[@r14]\]. This risk, typically defined as hypoglycemia requiring the assistance of another person, averages about two episodes per person per year \[[@r15]\]. T2D patients on insulin therapy have significant but substantially lower rates of hypoglycemia.

Despite huge unmet clinical need for therapies specifically approved for T1D and defined regulatory pathways for T1D indications \[[@r8], [@r16], [@r17]\], to date (and for a variety of reasons) no drug remains in Phase 3 development. Four drugs reached that stage, GAD65 (Diamyd), DiaPep277 (Andromeda), otelixizumab (GlaxoSmithKline), and teplizumab (Lilly/MacroGenics), but all have gone back to Phase 2 or have been discontinued.

Differences in Challenges and Opportunities for T1D and T2D Therapies
---------------------------------------------------------------------

Development of T1D and T2D therapies differ in both their challenges and opportunities. T1D is comprised of both an established orphan indication for new-onset T1D, defined by the US Food and Drug Administration (FDA) as a disease with fewer than 200,000 individuals affected, and a general indication for T1D as a disease that affects about 1.5 million people in the US. FDA has recognized that new-onset T1D represents an orphan population and has provided orphan designations to at least 10 different drugs and biologics \[[@r18]\].

In part because of the smaller population involved, FDA and the European Medicines Agency (EMA) require smaller development programs for T1D therapies than are required of T2D therapies. FDA notably expects the cardiovascular safety of T2D therapies to be systematically evaluated before and after approval. This is not the case for T1D therapies. FDA has not applied the same cardiovascular outcome trial (CVOT) requirement to insulin therapies, which are indicated for both T1D and T2D, but approval of NovoNordisk's long-acting insulin analog, insulin degludec (Tresiba^TM^), was held up by a requirement to complete a CVOT after FDA observed an adverse signal in the original new drug application \[[@r19]\]. Differences in regulatory expectations and clinical trial designs for various T1D therapies are compared in Table **[2](#T2){ref-type="table"}**.

Few, if any, current T2D products are more than just palliative approaches: they only reduce glucose, body weight, and/or insulin resistance. If a T2D drug regimen is removed from a patient, little, if any, benefit may remain. In contrast, many T1D therapeutic candidates, other than insulin products, have prospects to be either curative, restorative, and/or disease modifying.

Finally here, in contrast to individuals with T2D, those with T1D are generally diagnosed at a younger age, more adept with technology, more informed, and active in seeking better treatments.

NEW AND APPROVED VERSIONS OF APPROVED AGENTS/MECHANISMS OF ACTION FOR T1D DRUGS
===============================================================================

Insulin has been, and still is, the most important treatment for patients with T1D. Currently available insulins are not entirely effective in controlling blood glucose levels, as hyper- and hypoglycemia are still common in patients with T1D. Therefore, a high medical need exists for insulins, especially with less risk for hypoglycemia. The most frequent approach in this regard is to shorten the time-action profile of rapid-acting insulin to be more similar to physiologic insulin secretory profiles, thereby ameliorating post-prandial hyperglycemia which could eventually have benefits in fully automated closed loop settings. Moreover, new methods of insulin delivery, such as oral insulin, could be attractive treatment options for patients with T1D and T2D. Oral insulin delivery could also provide more physiologic exposure of insulin to the liver, and this might lead to less hypoglycemia risk and weight gain. "Smart insulin," insulin analogs with activity modulated by ambient blood glucose levels, is another approach for improving the therapeutic index of insulin \[[@r20]\].

The FDA and EMA require studies of both T1D and T2D patients for all insulin products. No indication has yet been approved for an insulin product that restricts use to one form of diabetes or the other.

Injectable Insulins
-------------------

New basal insulin analogs that lead to less glucose variability and less hypoglycemia risk and/or have a longer duration of action than currently available basal analogs are in development. LY2605541 (Lilly) is a pegylated insulin Lispro (pegLispro) that is intended for once-daily injection. The pegylation of the insulin is associated with a slower absorption and reduced clearance, resulting in a longer duration of action. A Phase 2 study in participants with T1D showed that pegLispro was more effective than insulin glargine with regards to glycemic control, and reduced the insulin doses needed for meals as well as body weight. The overall incidence of hypoglycemia was increased, but measures of nocturnal hypoglycemia were reduced compared with insulin glargine. Of concern, liver enzymes (alanine aminotransferase, aspartate aminotransferase), triglycerides, and LDL-cholesterol increased while HDL-cholesterol decreased compared with insulin glargine in this study \[[@r21]\]. The report of increased liver fat associated with this analog has led to a delay in regulatory filings, and Eli Lilly has eventually decided to terminate its development in December 2015 \[[@r22], [@r23]\].

A once-weekly basal insulin is in development by the South Korean company Hanmi (HM12460A). A Phase 1 study in patients with T1D has already been successfully completed \[[@r24]\]. NovoNordisk's once-weekly insulin LA1287 is currently in Phase 1 development for T1D (NCT01730014). Data are not yet publicly available.

No injected ultra-rapid-acting insulin product has yet been approved, but the approved pulmonary inhaled insulin product Afrezza^®^ does have a distinctly faster time-action profile than currently available injected insulin analogs (as discussed in due course). Injected ultra-rapid acting insulins and insulin analogs are in various stages of development. BIOD-123 (Biodel) proved noninferior compared with insulin lispro with regards to HbA1c (defined as the upper bound of the 95% confidence interval around change from baseline HbA1c of \<0.40%) in a Phase 2 study including 132 participants with T1D \[[@r25]\]. Linjeta™ (Biodel), another ultra-rapid acting insulin analog, completed Phase 3 development, but did not get approval from the FDA due to questions about efficacy, tolerability, and stability. The company, therefore, decided to go forward with a follow-on product, BIOD-123 \[[@r26]\]. NovoNordisk's faster acting insulin aspart (FI-ASP), a combination of insulin aspart, nicotinamide, and arginine, showed a significantly greater glucose lowering effect within 90 minutes and an earlier onset with a similar potency compared with insulin aspart \[[@r27]\]. Results from a Phase 3 trial in T1D patients showed a better HbA1c reduction with FI-ASP compared with insulin aspart \[[@r28]\].

An ultra-fast acting insulin lispro is co-developed by Adocia and Lilly using Adocia's Biochaperone^®^ technology, which attaches polymers to proteins and thereby stabilizes them and protects against enzymatic degradation. A Phase 2b trial in patients with T1D was initiated in August 2015 (NCT02528396) and the companies plan to initiate a Phase 3 trial soon \[[@r29]\].

Another interesting approach is the development of glucose-responsive insulins (smart insulins). These insulins would automatically activate once the blood glucose is high and be inactive when the blood glucose is low. Merck's MK-2640 is already in Phase 1 development (NCT02269735) but it will take some time until these smart insulins reach the market.

Halozyme is developing an adjuvant therapy for reducing the time-action profile of injected insulin. Halozyme's rHuPH20 is a recombinant human hyaluronidase that can be combined with rapid acting insulin analogues. This leads to a faster and more consistent absorption \[[@r30]\]. Phase 2 trials showed that insulin lispro or aspart combined with rHuPH20 were noninferior to insulin lispro alone and reduced post-meal glucose excursions by 82% and hypoglycemias by 5-7% \[[@r31]\].

Pulmonary Insulin
-----------------

The only inhaled insulin product to be approved to date is Afrezza^®^ (Mannkind), which does have a distinctly faster time-action profile that injected insulin analogs. It is noteworthy that FDA has not permitted Afrezza^®^ the use of the term 'ultra-rapid' insulin, even though its time-action profile is clearly different from fast acting insulins \[[@r32]\].

Another inhaled insulin product is under development by Dance Biopharm. Dance's product consists of a pocket-sized inhaler device and insulin container. In contrast to the dry powder form of the insulin used in the Afrezza^®^ device, the Dance insulin formulation is packaged as a liquid in a separate container. A few drops of the liquid formulation can be accurately dispensed into the reservoir on top of the device for dosing at mealtime. The Dance drug-device combination product has completed Phase 2 clinical trials and is in preparation for pivotal development \[[@r33]\].

Oral Insulins
-------------

Delivering insulin orally to achieve therapeutically relevant circulating insulin levels is a promising approach for improving glycemic control in patients with T1D. Oral delivery can provide a more physiologic presentation of insulin to the liver than that provided by peripherally injected insulin. Endogenous insulin is subject to a first-pass effect in the liver, which modulates the appearance of insulin in the periphery. The higher portal insulin concentration that results from pancreatic insulin secretion leads to a greater suppression of hepatic glucose production than can be achieved with peripherally injected insulin \[[@r34], [@r35]\]. If oral insulin is absorbed from the gastrointestinal tract into the portal venous system, this can lead to effects in the liver similar to those resulting from physiologic insulin secretion. This contrasts with injected insulin, which immediately exerts systemic action. Thus, enterally absorbed oral insulin treatment might be a way to smooth the glucose profile and reduce the risk of hypoglycemia compared with parenteral insulin. Although oral insulin may not replace parenteral insulin for patients with T1D, the addition of oral insulin could reduce the amount of parenteral insulin needed and improve glycemic control and risks of hypoglycemia \[[@r36]\]. A favorable benefit-risk profile has still to be shown in larger clinical studies, but currently available human data suggest that this might be a valuable approach for treating diabetes.

Several enterally absorbed oral insulins are in development. A short-acting oral insulin currently in Phase 2 development for T1D is ORMD0801 (Oramed). A Phase 3 study of IN-105 (Biocon) has already been conducted in India in T2D. A Phase 1 study in T1D has been initiated (NCT01035801) but there are no other public data on IN-105 available in T1D. Basal oral insulins are in earlier stages of development. As one example, OI287GT (NN1956) (NovoNordisk) is in Phase 1 development but information on studies employing participants with T1D is not yet available (NCT01809184).

Another way to administer insulin orally is buccal administration. Oral-lyn^TM^ (Generex) is a human insulin spray to deliver insulin *via* the buccal wall for T1D and T2D patients \[[@r37]\]. It is not approved by the FDA or EMA but is available in some non-US and non-EU countries. Oral-lyn was marketed in India, but its approval was rescinded in 2009 \[[@r38]\]. Generex announced in 2013 that its Indian licensee, Shreya Life Sciences Pvt. Ltd., had completed a local Phase III trial of the buccal insulin product (branded as Oral Recosulin^®^ in India) and submitted the dossier to the Drugs Controller General (India) (DCGI) \[[@r39]\]. There is currently no information available from Generex on the status of the DCGI submission or its plans to seek FDA or EMA approval.

Hepatoselective Insulin Product
-------------------------------

The development of oral insulin products represents one example of a parallel and more general effort to increase the insulinization of the liver, which could improve the therapeutic index of insulin treatment. Targeting of insulin to the liver or enhancing liver selectivity of insulin products has a long history \[[@r40]\]. A recent example of a hepatoselective insulin program is Lilly's long-acting basal insulin, LY2605541, discussed previously. This pegylated insulin analog showed direct evidence of hepatoselectivity \[[@r41]\] and compared well to basal insulin glargine in clinical trials \[[@r21]\], but development was terminated in December 2015 related to the association of increased hepatic fat with treatment \[[@r23]\].

Diasome Pharmaceuticals is developing a novel means of targeting insulin delivery to the liver. Diasome's approach consists of insulin-containing vesicles. The vesicle is coated with a ligand that is avidly taken up by the liver \[[@r42]\]. Preliminary clinical studies have provided evidence of increased insulin activity at the liver relative to insulin comparators \[[@r43]\]. The company is currently planning a Phase 2b trial in collaboration with the Joslin Clinic \[[@r44]\].

DRUGS APPROVED FOR T2D SEEKING AN INDICATION FOR T1D
====================================================

Sodium/Glucose Cotransporter (SGLT) Protein Inhibitors
------------------------------------------------------

SGLT2 inhibitors reduce blood glucose levels by lowering the renal threshold of glycosuria. Given their insulin-independent mechanism of action, SGLT2 inhibitors could be helpful to the management of T1D when given as an add-on therapy to insulin. Some of these agents that are already approved for the treatment of T2D are being investigated to pursue an indication for T1D, *e.g*., empagliflozin, dapagliflozin and canagliflozin. Empagliflozin (Jardiance ^®^ - Boehringer Ingelheim/Eli Lilly) was studied in a Phase 2 clinical trial (NCT01392560) in 40 participants with T1D to investigate renal hemodynamic effects and glucose efficacy as an exploratory endpoint. Treatment with empagliflozin for 8 weeks demonstrated a 0.4% decrease in average HbA1c, which was also followed by a decrease in mean fasting glucose and total daily insulin dose. Interestingly, there were also reductions in hypoglycemic events, weight (mean of 2.6 kg), and waist circumference \[[@r45]\].

Of considerable note, the recent results of the large CVOT with empagliflozin in T2D demonstrated cardiovascular benefits, *i.e*., a 38% reduction in risk of cardiovascular death and a 35% relative risk reduction in hospitalization for heart failure as compared with standard-of-care. While still not completely explained, these findings indicate an advantage for the treatment of T2D with stablished cardiovascular disease, although it is too early to speculate whether empagliflozin could provide similar cardiovascular benefit in patients with T1D \[[@r46]\].

Improvements in measures of glucose control in T1D were also shown with dapagliflozin (Farxiga^®^ - Astra Zeneca). In a 2-week Phase 2a trial employing 70 participants with T1D, dapagliflozin as compared with placebo showed greater numeric reductions in mean blood glucose levels over 24 hours and mean amplitude of glucose excursions measured by continuous glucose monitoring, as well as a decrease in total daily insulin dose \[[@r47]\]. These results from short-term treatment still need to be confirmed in longer duration studies to support a future indication of this agent for T1D.

Canagliflozin (Invokana^®^ -- Janssen) is another SGLT2 approved for T2D that is currently being tested in T1D (NCT02139943). Ipragliflozin (Suglat^®^ - Astellas Pharma), an SGLT2 approved in Japan, was tested in animal models of T1D \[[@r48]\]. Among the SGLT2 inhibitors still in earlier phases of clinical development, remogliflozin (BHV Pharma) is in Phase 2 development for T2D and in Phase 1 for T1D, with initial positive safety findings from a single dose administration as an add-on to continuous insulin infusion \[[@r49]\].

While the anti-hyperglycemic effect of SGLT2 inhibitors is primarily due to its action at the renal tubule, SGLT1 inhibitors have been shown to target the gut absorption of glucose, which can reduce post-prandial glucose excursions. No SGLT1 inhibitor has yet been studied in T1D. Sotagliflozin (LX4211, Lexicon Pharmaceuticals) is a combined SGLT1/2 inhibitor in Phase 3 development, which has been successfully tested in T2D and T1D, and it is therefore positioned to become the first in this class to gain approval for treatment of T1D \[[@r50]\]. Results of the Phase 2 proof-of-concept trial of sotagliflozin in 33 participants with T1D (NCT01742208) treated for 29 days showed a superior reduction of total daily mealtime insulin dose compared with placebo (32% vs 6.4%) and improved glucose control with higher reduction of HbA1c (0.55% vs 0.06%) \[[@r51]\]. Continuous glucose monitoring evaluation showed reduction in time in the hyperglycemia range without increase of hypoglycemia. Continuous glucose monitoring evaluation additionally demonstrated greater percentage of time in the target glycemic range with sotagliflozin compared with placebo (68.2% vs 54.0%) and reduction in time in the hyperglycemia range (25.0% versus 40.2%), without increase of hypoglycemia \[[@r52]\].

Overall, SGLT inhibitors carry a promise of improving glucose control while promoting a moderate weight loss and providing some additional cardiovascular benefits, such as reduction of systolic blood pressure, renal hyperfiltration, and albuminuria \[[@r53]-[@r56]\]. Although less of a concern for the majority of patients with T1D than is the case for T2D patients, excess weight gain is still an important drawback of insulin therapy. Though understanding of the metabolic and hemodynamic effects of this class is incomplete, T1D patients may potentially benefit from an additional improvement in glucose control provided by an oral agent that decreases insulin requirements and thereby decreases hypoglycemia risk. Despite the optimistic efficacy results demonstrated in short-term studies, further studies are needed to assess the safety profile of these agents in people with T1D, particularly children. The clinical relevance of adverse events reported in T2D and T1D studies, such as higher rates of genitourinary infections, requires special attention in this population given the possible long term impact on clinical outcomes and quality of life. Of concern for use of SGLT2 agents in T1D are the recent reports from FDA and EMA of the association of SGLT2 agents with diabetic ketoacidosis (DKA) \[[@r57], [@r58]\]. Most of the cases were T2D patients, but a few were T1D patients. Presumably the risk of DKA in T1D patients would be at least as high as that for T2D patients, but the risks related to SGLT2 inhibitors for both T1D and T2D patients are not yet clear \[[@r59]\]. A recent report described 13 episodes of SGLT2 inhibitor associated diabetic ketoacidosis in 7 T1D and 2 T2D patients \[[@r60]\]. Studies of newer agents in this class and studies of a longer duration of marketed products will help to characterize more fully the benefits and risks of SGLT2 inhibitors in T1D.

GLP-1 Agonists
--------------

Glucagon-like peptide-1 (GLP-1) is secreted from the gut after meals and enhances glucose-induced insulin secretion, inhibits glucagon secretion, suppresses appetite, and delays the gastric-emptying rate. GLP-1 receptor agonists represent a class of drugs that has traditionally been used in the treatment of adults with T2D. GLP-1 agonists have demonstrated several advantages over previously approved therapies, including less risk of hypoglycemia compared with insulins and insulin secretegogues and promotion of weight loss.

It has been suggested that the use of GLP-1 receptor agonists in T1D may reduce excessive postprandial glucagon secretion allowing patients to reduce their total daily dose of exogenous insulin \[[@r61]\]. Hypoglycemia risk may also be minimized in T1D as glucagon counter-regulation can be preserved to some degree *via* the glucose-dependent action of the GLP-1 receptor agonists. GLP-1 agonist therapies have shown some promising effects in terms of positively affecting overall β-cell health and increasing β-cell mass, primarily in mouse models.

Achieving good glycemic control with insulin therapy in T1D patients is necessary to prevent both microvascular and macrovascular complications \[[@r62]\]: however, insulin therapy also promotes unwanted weight gain \[[@r63]\]. Given that approximately 40% of patients with T1D now also carry the diagnosis of metabolic syndrome, investigating the therapeutic employment of GLP-1 agonists as a supplemental therapy in T1D is logical: the glucose-lowering effects resulting from the inhibition of glucagon secretion and the gastric-emptying rate could be of clinical importance.

In one study, 17 participants with T1D, half of whom had residual insulin production, underwent two mixed meal tolerance tests (MMTTs) and two intravenous glucose tolerance tests (IVGTTs), with and without pre-treatment with exenatide. This study showed significant acute metabolic effects in T1D participants following an oral meal in individuals with T1D, involving reduced glucose excursions, glucagon suppression, and delayed gastric emptying, while preserving insulin secretion in participants with residual insulin production. Despite the small number of individuals studied, the antidiabetic effects observed indicate a potential value for GLP-1 analogs as adjunctive treatment in T1D, especially in the new-onset period \[[@r64]\].

Several small nonrandomized studies with liraglutide employing individuals with T1D have demonstrated that liraglutide, a long acting GLP-1 receptor agonist, resulted in improved glycemic control and led to weight loss \[[@r65]\].

A retrospective analysis of data obtained from 27 obese individuals with T1D treated with insulin and liraglutide in addition to being treated for hypertension was reported by Kuhadiya *et al* \[[@r66]\]. Results demonstrated that after 180 ± 14 days of treatment with liraglutide, mean glucose concentrations fell from 191 ± 6 to 170 ± 6 mg/dL (P = 0.002). HbA1c fell from 7.89 ± 0.13% to 7.46 ± 0.13% (P = 0.001), without an increase in frequency of hypoglycemia. Mean body weight fell from 96.20 ± 3.68 kg to 91.56 ± 3.78 kg (P\<0.0001). Daily total and bolus doses of insulin fell from 73 ± 6 to 60 ± 4 units (P = 0.008) and from 40 ± 5 to 29 ± 3 units (P = 0.011), respectively. Mean systolic blood pressure fell from 130 ± 3 to 120 ± 4 mm Hg (P = 0.020).

However, NovoNordisk recently announced that it will not submit an application to expand the label of liraglutide for use in T1D due to results of two large Phase 3 trials involving 2,000 participants with T1D. Liraglutide reduced the HbA1c but showed a higher rate of symptomatic hypoglycemia events compared with placebo \[[@r67]\]. Currently, only exenatide is still being studied in T1D. It remains to be seen if this GLP-1 agonist will differ from liraglutide in hypoglycemia risk.

IMMUNOMODULATORY DRUGS
======================

Interventions against the underlying autoimmunity of T1D fall into the two broad categories of auto-antigen and non-specific immunomodulatory or anti-inflammatory approaches. Auto-antigen approaches have emerged from the quest to understand the fundamental mechanisms of T1D autoimmunity. Insulin and glutamic acid decarboxylase (GAD) emerged as leading auto-antigen prospects for inducing tolerance, but trials with these auto-antigens have been largely unsuccessful.

Autoantigen Intended to Induce Tolerance
----------------------------------------

Autoantigen therapies have been suggested for induction of immune tolerance in T1D, although results so far have not been promising \[[@r68]\]. In the DPT-1 trial, subcutaneous low-dose insulin did not have any effect in preventing diabetes in first- and second-degree relatives of patients with T1D \[[@r69], [@r70]\], although a study of orally administered insulin continues. Similarly, intranasal insulin did not prevent or delay T1D in young children with increased genetic susceptibility to T1D \[[@r71]\].

### Glutamic Acid Decarboxylase (GAD65) as Vaccine

Diamyd^®^ is a vaccine-like product consisting of the 65-kD isoform of glutamic acid decarboxylase (GAD65) formulated with alum (GAD-alum). It has been studied extensively and found to have a good safety profile. The development program was discontinued in 2011 after the first Phase 3 trial failed to meet the primary endpoint of area under the curve for meal-stimulated C-peptide after 15 months of treatment \[[@r72]\]. Nonetheless, Diamyd Medical started further developing this vaccine in 2012. Several approaches to treat T1D are now being tested with Diamyd^®^, including trials started in 2015 in which this vaccine is directly injected into lymph nodes and combined with Vitamin D in newly diagnosed T1D patients (DIAGNODE-1, NCT02352974) or combined with gamma-aminobutyric acid (GABA) to preserve the residual insulin-producing capacity in 75 newly diagnosed patients aged 4-18 years (NCT02352974). In addition, a prevention trial in pediatric patients with multiple islet cell autoantibodies was initiated in 2015 (DiAPREV-IT, NCT 01122446).

### TOL-3021

TOL-3021 (Tolerion Inc.) is a novel reverse vaccine that induces tolerance with the autoantigen proinsulin, thereby reducing islet autoimmunity \[[@r73]\]. In a Phase 2a study, 80 participants with T1D (diagnosed within 5 years) were randomized to 4 different doses of TOL-3021 or placebo (administered intramuscularly) once weekly for 12 weeks, and were followed for 6 months. At Week 15 after baseline, C-peptide levels were improved in all dose treatment arms compared with placebo, and CD8 proinsulin-reactive T cells decreased in the active treatment arms \[[@r74]\].

Non-specific Immunomodulatory or Anti-inflammatory Agents
---------------------------------------------------------

The hallmark of T1D is autoimmune destruction of islet β-cells. The pathogenesis of this destruction is increasingly understood to be complex and heterogeneous. It is now known that, in addition to T-cell mediated destruction of β-cells and induction of β-cells giving rise to autoantibodies, there is neutrophil infiltration to both the endocrine and exocrine pancreas as well as involvement of dendritic cell, B1 cells, and IL17+ γδ T lymphocytes. In addition, cytokine release, such as IFNγ and inflammation, plays a key role. However, the insulitis, as well as β-cell destruction and residual function, is variable histologically, as is the rate of β-cell loss and dysfunction. Thus, the therapies discussed next target several of these pathways by which β-cell destruction may be mediated.

### Alpha-1 antitrypsin (AAT)

Human AAT is a serine protease inhibitor, mainly synthesized in the liver (\>80%), and in smaller quantities in the lungs, pancreas, enterocytes, and macrophages. AAT deficiency is associated with lung emphysema, intrahepatic obstruction and liver cirrhosis, panniculitis, and systemic vasculitis. An increasing amount of evidence over the last 10 years suggests that AAT has important anti-inflammatory, anti-apoptotic, and immunomodulatory properties not related to its anti-protease activity. These properties include the following: inhibition of nitric oxide (NO) production \[[@r75]\]; suppression of the synthesis of proinflammatory cytokines, such as IL-6, IL-8, IL-1β, and TNF-α \[[@r76]\]; prevention of pancreatic β-cell and bronchial epithelial cell apoptosis \[[@r77], [@r78]\]; and inhibition of caspases 3 and 6 \[[@r79]\]. Accordingly, administration of AAT in non-deficient individuals could potentially modify disease progression in a variety of clinical conditions, such as T1D, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and graft-versus-host disease \[[@r80]\]. Specifically for T1D, recently diagnosed individuals have decreased circulating levels of serum AAT, as well as increased enzymatic activity of neutrophil serine proteases, which could be implicated in the β-cell autoimmunity \[[@r81]\].

AAT is commercially available as an intravenous infusion in various countries, prepared from pooled plasma of blood donors: Omnio Bio Pharmaceuticals has announced the first-in-class recombinant version of human AAT.

A Phase 1/2 study of Glassia^®^ (a plasma-derived AAT produced by Kamada Pharma) in 24 pediatric participants with recently diagnosed T1D showed that the treatment was safe and decreased HbA1c from a mean of 8.43% to 7.09% \[[@r82]\]. A pivotal placebo-controlled Phase 2/3 trial in 192 participants with new-onset T1D is currently ongoing (NCT02005848). A Phase 2 study with another AAT preparation (Prolastin-C^®^, Grifols Therapeutics, NCT02093221) is currently ongoing, but data are not yet available.

### Anti-CD3 Antibodies

CD3 is an essential component of the T-cell receptor complex and transduces signals to activate mature T-cells. Therefore, inhibiting CD3 is a plausible way to reduce T1D autoimmunity. Several anti-CD3 antibodies have been approved for acute and/or chronic rejection of solid organ transplants, including the first ever approved monoclonal antibody for human use, muromonab-CD3. Newer anti-CD3 antibodies, teplizumab, visilizumab, and otelixizumab have been developed for T1D. Visilizumab was in Phase 2/3 development for T1D but was terminated due to less favorable safety and efficacy profiles compared with other members of its drug class.

Teplizumab (MacroGenics) is an anti-CD3 epsilon chain monoclonal antibody in development for prevention of T1D. Studies have shown teplizumab increases CD8, CD25+ Tregs, thus inhibiting the CD4+ effector cells \[[@r83]\]. In the last decade, there were multiple trials demonstrating the efficacy of teplizumab in preserving post-MMTT C-peptide levels. These included smaller trials employing participants diagnosed with T1D within 6 weeks of enrolment and followed for 2-5 years (NCT00378508) \[[@r84], [@r85]\]. Also, the Phase 2 open-label AbATE trial, which enrolled 81 participants with T1D diagnosed within 6 weeks prior to enrolment, showed preservation of post-MMTT C-peptide by 75% in the treatment arm compared with placebo one year later (NCT00129259) \[[@r86]\]. A follow-up observational trial of AbATE is ongoing (NCT02067923).

However, the development of teplizumab for the treatment of T1D was discontinued after the Phase 3 554-participant PROTÉGÉ trial did not meet the composite endpoints of HbA1c (\<6.5%) and insulin dose reduction (\<0.5 U/kg/day) after one year (NCT00385697) \[[@r87]\]. Despite this, teplizumab was effective in maintaining post-MMTT C-peptide levels in subpopulations with higher C-peptide level and lower insulin dose at the start of the trial, a more recent diagnosis (6 weeks rather than 12 weeks), and younger age. Teplizumab was well tolerated, with the main adverse reactions being rash and transient decreased lymphocytes. Similar results were reported after two years \[[@r88]\].

In conjunction with nonclinical data, these results led to a now-ongoing trial examining teplizumab therapy for T1D prevention, targeting pre-diabetic individuals who have two or more auto-antibodies and are relatives of T1D patients (NCT01030861). There is also a Phase 3, 250-participant PROTÉGÉ ENCORE trial studying the efficacy of teplizumab in treating T1D with two 14-day courses (NCT00920582). The trial is completed but results are not yet released.

Otelixizumab (GlaxoSmithKline) is another anti-CD3 monoclonal antibody that is back in development after its Phase 3 program was discontinued. Earlier trials had shown efficacy using 48 mg cumulative dose and follow-up as long as 48 months (NCT00627146) \[[@r89], [@r90]\]. However, the pivotal Phase 3 trial (DEFEND-1) enrolled 281 participants with T1D diagnosed less than 90 days prior to enrolment and administered 3.1 mg total dose of otelixizumab to avoid the higher-dose-induced EBV mononucleosis and cytokine release syndrome (NCT00678886) \[[@r91]\]. While there were no EBV reactivations, the efficacy endpoint of post-MMTT C-peptide was not achieved. Following this, the second Phase 3 trial DEFEND-2 was terminated early after 12 months and the results were similar (NCT011230830) \[[@r92]\].

Currently, the ongoing Phase 2 trial is aimed to examine the safety and tolerability of otelixizumab between 9 mg and 36 mg with post-MMTT C-peptide as a secondary endpoint. This trial will enroll 40 participants in Belgium, and last 5 years.

### Abatacept

Abatacept modulates T-cell co-stimulation and prevents full T-cell activation. In this manner it could have an influence on the progression of T1D. It was shown that Abatacept can delay the C-peptide decline in patients with recent-onset T1D during 2 years of treatment \[[@r93]\]. This effect is sustained for at least 1 year after cessation of treatment \[[@r94]\]. Currently, abatacept is evaluated for prevention of abnormal glucose tolerance in patients at risk for T1D (NCT01773707).

### Rituximab

Treatment with the selective β-lymphocyte depletion agent rituximab, an anti-CD20 monoclonal antibody, for 1 year delayed the C-peptide decline in patients with recent-onset T1D \[[@r95]\]. However, this approach for T1DM treatment is not pursued anymore as it could not significantly influence its pathophysiology.

### DiaPep277

DiaPep277 (Hyperion Therapeutics) is a 24 amino acid peptide corresponding to positions 437-460 in heat shock protein 60 (HSP60). The peptide has been show to modulate immunological attack on β-cells in the NOD mouse model of type 1 diabetes \[[@r96]\]. Phase 2 studies showed that this peptide can inhibit the decline in stimulated C-peptide secretion in adult T1D patients \[[@r97]\]. The first of two Phase 3 studies was published in 2014. However, the publication was retracted and the second Phase 3 trial results have not been released. The development of DiaPep was discontinued after Hyperion Therapeutics, Inc., which acquired Andromeda Biotech in June 2014, uncovered evidence of study misconduct during this Phase 3 study \[[@r98]\].

### Dendritic Cells

Dendritic cells (DC) are antigen-presenting cells that can initiate the immune response, while also participating in peripheral T-cell tolerance \[[@r99]\]. Tolerogenic DCs could potentially be useful in the management of autoimmune conditions, such as rheumatoid arthritis, solid organ transplantation, and T1D. Creusot *et al.* \[[@r100]\] provided a review of the use of DCs in T1D.

DiaVacs Inc. has developed vaccine DV0100, which aims to reverse recent-onset T1D. DV0100 obtained orphan-drug status from FDA in 2014. The vaccine is based in leukapheresis-harvested autologous DCs, engineered *via* incubation with antisense DNA oligonucleotides that target CD40, CD80, and CD86, followed by their administration in the peri-umbilical area of the individual. These cells are called "immunoregulatory" DCs (iDCs).

A Phase 1 study in 10 participants with T1D duration greater than 5 years reported no safety issues for this vaccine \[[@r101]\]. Phase 2 studies targeting patients earlier after their diagnosis (\<6 months) are currently planned: no data are yet available (NCT00445913, NCT01947569).

Anti-Cytokines
--------------

### Anti-IL-17

PF-06342674 (Pfizer) is a monoclonal antibody antagonizing both IL-7 and IL-17 receptors. IL-7 stimulates the proliferation of lymphoid cells, whereas IL-17 stimulates production of many chemokines important for chemotaxis of myeloid cells. A Phase 1 trial (NCT01740609) employing 80 healthy participants and assessing the compound's safety and tolerability has been completed but results are not publicly available. In 2014, a Phase 2 trial (NCT02038764) in T1D adults diagnosed within two years of randomization was initiated to assess safety, tolerability, pharmacokinetics, and immunogenicity by subcutaneous administration.

### IL-1 Modulators

The IL-1 pathway is involved in autoimmune and auto-inflammatory diseases \[[@r102]\]. IL1-α activation leads to synthesis of the more potent IL-1β in many cell types. Both IL-1α and IL-1β bind to IL-1 receptor 1 (IL-1R1) and activate multiple intracellular signalling cascades leading to activation of NFκB and AP-1. Furthermore, hyperglycemia and high circulating free fatty acids activate β-cells to increase IL-1β by more than 100-fold. This leads to β-cell dysfunction and death.

Canakinumab (Novartis) is approved for cryopyrin-associated periodic syndromes, gouty arthritis, and juvenile rheumatoid arthritis. Canakinumab binds selectively to IL-1β and competitively prevent its binding to the IL-1 receptors. The drug has been shown to be well tolerated in multiple clinical trials for inflammatory diseases. However, a Phase 2 trial designed to assess the change in C-peptide levels after MMTT in participants with T1D diagnosed within the previous 3 months was terminated in 2011. In 2013, Moran and co-workers reported on behalf of the Type 1 Diabetes TrialNet Study Group that monthly injection of canakinumab for 12 months in individuals with newly diagnosed T1D did not lead to statistically significant improvement in post-MMTT C-peptide level compared with placebo \[[@r103]\]. Currently, the compound's development for T1D has been terminated. However, although monotherapy may not be effective, this drug may be useful in combination therapy with other immune-modulators.

Gevokizumab (Xoma), a monthly injectable drug, is being developed in Phase 2 in Switzerland for T1D. It binds selectively to IL-1β and allosterically reduces its binding affinity to the IL-1 receptors, but not its decoy receptor that leads to its degradation \[[@r104]\]. It is being developed in a Phase 3 program for non-infectious uveitis and has been found to be safe and well tolerated. Two Phase 2 trials (NCT01788033, NCT00998699) have been completed for T1D. Both are randomized double-blind, placebo-controlled trials evaluating the effect of gevokizumab after 4 months of monthly subcutaneous injection on post-MMTT C-peptide levels in adults with T1D on stable dose of insulin and diagnosed more than two years prior. The results are not yet published.

### Anti IL-12 and IL-23

Ustekinumab is a human monoclonal antibody directed against IL-12 and IL-23 and is indicated for the treatment of psoriasis. It is currently being investigated in a Phase 1/2 study for the treatment of recently onset T1D \[[@r105]\] and in combination with the islet regeneration agent, INGAP Peptide \[[@r106]\].

Non-specific Immunosuppressant
------------------------------

Antithymocyte globulin (ATG) (Genzyme) has been approved for transplant rejection and aplastic anemia. It leads to lysis of T-cells as well as altered T-cell function, thus reducing immune competence. It has been in Phase 2 development for T1D. The Phase 2 trial, Study of Antithymocyte Globulin for Treatment of New-onset T1DM (START) (NCT00515099), was terminated due to slow recruitment \[[@r107]\]. This was a 2-year study in newly diagnosed diabetic patients comparing ATG with placebo. ATG was given by infusion and required hospitalization for 5-8 days. Results showed no difference between the ATG and placebo groups for 2- or 4-hour AUC C-peptide production after a MMTT both 1 and 2 years after infusion. While there was no difference in insulin usage, there was a trend toward better HbA1c at both one and two years in favor of ATG. Additionally, the ATG group had increased adverse reactions, including serum sickness and cytokine release syndrome.

Another Phase 2a trial (NCT01106157) focused on T1D diagnosed between 4 months and 2 years before enrolment to assess the preservation of β-cell function comparing combination treatment of ATG plus GCSF with placebo \[[@r108]\]. Results showed stable post-MMTT C-peptide in the treatment group comparing with declining C-peptide in the placebo group after 6 and 12 months, with no statistical significant difference in daily insulin requirement or HbA1c. Currently, a Phase II trial (NCT02215200) is recruiting participants with T1D diagnosed within 100 days of enrolment with residual β-cell function to assess the effect of antithmocyte globulin alone and in combination with granulocyte colony stimulating factor (GCSF) on C-peptide production.

Miscellaneous Approaches
------------------------

### Imatinib (Tyrosine Kinase Inhibitor)

Imatinib is marketed by Novartis as Gleevec^®^ and is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). It has been shown that imatinib can reverse T1D in prediabetic and new onset diabetic mice \[[@r109]\]. This is further investigated in a currently ongoing Phase 2 study in patients with a recent onset of T1D (NCT01781975).

### VGX-1027

VGX-1027 (Inovio Pharmaceuticals) is an orally active small molecule that inhibits the NF-kB and p38 MAPK pathways while not affecting JNK and Ap-1 pathways. It also suppresses toll-like-receptor-mediated production of TNF-α, IL-1β, and IL-10. Nonclinical research showed that VGX-1027 reduced the onset of autoimmune diabetes in non-obese diabetes mice and inhibited diabetes induced by streptozotocin \[[@r110]\]. Two Phase 1 trials have been completed (NCT00627120, NCT00760396), showing a safe and tolerable profile \[[@r111]\].

### Ladarixin

Ladarixin (Dompé) is an orally active sulfonamide that allosterically inhibits IL8a/CXCR1 and IL-8b/CXCR2 receptors \[[@r112]\]. IL8/CXCL8 is a potent chemo-attractant of neutrophils and other cells contributing to inflammation. In mice T1D models, blocking the CXCL8 pathway with ladarixin decreases infiltration of immune cells, improves islet cell survival, and delays onset of diabetes \[[@r113]\].

### Therapies to Reduce β-cell Stress

Some evidence suggest that stress to the endoplasmic reticulum (ER) may have a role in mediating autoimmune β-cell destruction. Tauroursodeoxycholic acid (TUDCA) significantly reduced the T1D incidence in mice at risk for T1D, and this effect was attributed to reduction of ER stress \[[@r114]\]. The effect of TUDCA on the progression of new-onset T1D is now being tested in a clinical study (NCT02218619).

Polyamines appear to play a role in the progression of cellular inflammation. Depletion of intracellular polyamines with diflouoromethylornithine (DFMO) reduced the incidence of diabetes in mouse models of autoimmune diabetes \[[@r115]\]. DFMO is now being tested in a clinical trial in children with recent-onset T1DM (NCT02384889).

AGENTS THAT REGENERATE Β-CELLS
==============================

Pathogenesis of T1D clearly involves the autoimmune destruction of pancreatic β-cells with consequent insulin deficiency. Most T1D disease-modifying therapies under development target the autoimmune process, but relatively little attention has been given to research of agents inducing β-cell regeneration or islet neogenesis to restore pancreatic mass and insulin secretion. The islet neogenesis associated protein (INGAP) is a protein extracted from obstructed pancreatic ducts of hamsters that has been found to induce *in vitro* pancreatic cell neogenesis \[[@r116]\]. INGAP belongs to the REG family of cell surface binding proteins encoded by REG genes expressed in gastrointestinal tissues of several species (mouse, hamster, rat, and humans). REG gene expression is mainly linked to islet formation during fetal development, but these genes can also be expressed later in life in response to pancreatic cell injury and are associated with islet regeneration \[[@r117]\]. INGAP peptide (INGAPP) corresponds to the 15 amino-acid sequence that retains the islet regeneration activity of INGAP \[[@r118]\].

In nonclinical studies, INGAPP (Exsulin Corporation) has been shown to result in a dose-dependent stimulation of proliferation of β-cell mass in different species (rodents, dogs, and cynomolgus monkeys) \[[@r119]\] and increased insulin secretion in response to glucose in pancreatic rat islets, as well as induced transcription of several islet genes involved in the β-cell metabolism \[[@r120]\]. In Phase 2 studies, once-daily subcutaneous infusions of INGAPP for 90 days led to an increase in C-peptide secretion in T1D (NCT00071409) and modest decreases in HbA1c and mean glucose in T2D individuals (NCT00071422) at the highest dose level, although adverse events were a main reason for discontinuation (12% in T1D and 9% in T2D) \[[@r121]\].

Exsulin conducted trial E-201 in T1D patients (NCT00995540) to evaluate tolerability and efficacy of *tid* administration of 300 mg and 600 mg for 12 weeks. The study was terminated due to lack of observed efficacy with the *tid* regimen. Trial E-203 to test safety and efficacy of a combination of INGAP with ustekinumab, an IL-12 antagonist approved for the treatment of plaque psoriasis (NCT02204397) has just started \[[@r122]\]. Despite the promising effects in T1D and T2D, issues with short half-life and low bioefficacy may necessitate large doses, leading to injection site reactions, low tolerability, and elevated costs.

Another REG-encoded peptide, the human proislet peptide (HIP), has also been identified and associated with enhanced *in vitro* insulin production in human pancreatic ductal tissue and increased islet cell mass with improved glucose control in diabetic mice \[[@r123]\]. HIP2B (Pancreate^TM^, CureDM/Sanofi) is a stabilized form of HIP that demonstrated positive nonclinical results and is currently in Phase 1b in T2D individuals (NCT01933256). The results of this study may indicate whether this can also become a potential therapeutic target for T1D.

Another peptide with similar properties, PRL-002 (Perle Bioscence), is reported to be in nonclinical development, and an IND application is expected in 2016. The encouraging initial results from the few compounds in development in this group, as well as an acceptable safety profile, still need to be confirmed in later-phase clinical trials before one can be confident that the concept of islet regeneration is a promising approach for T1D. Even if not completely curative alone, pharmacologic induction of islet regeneration may restore some level of insulin secretion sufficient to improve treatment outcomes.

CONCLUDING COMMENTS
===================

Patients with T1D need additional treatment options, and ultimately a cure. A recent prospective cohort study from 2008 through 2010 of all individuals alive in Scotland with T1D who were aged 20 years or older and were in a nationwide registry found that the average man with type T1D subsequently had an estimated life expectancy loss of approximately 11 years; the respective figure for women was approximately 13 years \[[@r124]\]. Regulatory agencies recognize the need for effective and timely advances within this  particular therapeutic area. In July 2015, FDA issued a report entitled "Targeted Drug Development: Why Are Many Diseases Lagging Behind?" \[[@r125]\]. In this report, diabetes in general, and T1D specifically, is identified as an area of great importance. Regarding diabetes, the reports reads as follows:

More basic research is needed to increase scientists' understanding of the interaction between genetic, immunologic, metabolic, and environmental factors that cause specific subsets of patients to develop the disease and why the progress, signs, and symptoms of the disease are variable from patient to patient. Scientists still need to understand much more about why and how the immune system attacks the pancreas, to allow development of treatments that target the specific auto-immune process rather than suppressing the entire immune system, which carries serious risks. Further research is also needed to find biomarkers for susceptibility to specific complications of diabetes (as opposed to the disease itself).

FDA and EMA stand ready to approve disease modifying therapies for T1D. and have expressed reasonable expectations for demonstrating efficacy of therapies aimed at preserving insulin secretion in new onset patients. It is unclear what minimum treatment effect on preservation of C-peptide secretion, the regulatory primary efficacy endpoint, would be considered clinically meaningful for a new onset intervention. A small effect size (10-20% at two years) might be enough if the safety profile is very benign. Therapies that result in significant immune deficits or other toxicities would require much higher treatment effects. To power a two-year trial adequately to detect a 15% treatment effect would require several hundred participants in each treatment group. Larger effect sizes enable much smaller trials, but the statistical power of the typical Phase 3 trial to date \[[@r126]\] potentially leaves clinically meaningful effects on the table. FDA and EMA will also require some evidence for positive effects among important secondary outcomes such as HbA1c, rates of hypoglycemia, and total daily injected insulin dose. However, there are substantial challenges in new onset T1D trials to demonstrating robust effects on these secondary endpoints \[[@r127]\].

Going Forward
=============

A single silver bullet for safely eliminating T1D autoimmunity is not on the horizon and perhaps will never be found. For the foreseeable future, a combination of therapies will be needed to control β-cell destruction, analogous to the paradigm of T2D treatment. T1D combination therapy is not a novel concept \[[@r128]\]. Combination clinical trials have been attempted and continue to be initiated \[[@r106], [@r129], [@r130]\]. Combinations of two or more agents have been shown to induce remission in the standard NOD mouse model of established T1D \[[@r131], [@r132]\]. However, mice and humans differ substantially in both T1D autoimmunity and islet biology. The lack of a dependable animal model is a major impediment to identifying combinations of agents that could feasibly tested in humans \[[@r133]\]. Given the minimum necessary trial size and duration to achieve an efficacy readout for new onset T1D trials, the evaluation of more than two agents in a factorial design becomes impractical. More reliable nonclinical models are needed to winnow the number of multiple agents to what can feasibly be evaluated in patients. While FDA has provided a guidance for the co-development of experimental therapies \[[@r134]\], this does not make the task of developing combination therapies any easier. Regulatory authorities will continue to ask that the contributions of individual components be demonstrated \[[@r135]\]. The empiric, sequential paradigm utilized to evolve combinations of cancer chemotherapy agents over the past five decades could be employed but this would require a larger timeframe and use of resources than is available.

If effective control of T1D autoimmunity is achieved without a means of restoring endogenous insulin secretion, only people with new onset T1D or with an identifiably high-risk status for developing T1D will benefit. Residual insulin secretion is still present in many T1D patients diagnosed more than 3 years in the past \[[@r136]\]. Therefore, the identification of safe and effective islet regeneration agents holds great promise and will extend the benefits of autoimmunity control to the general 1.5 million people in the US alone.

From a clinical evaluation standpoint, the development of islet regeneration agents is much easier than the case for evaluating immunomodulatory agents in new onset patients. People with established T1D have little or no endogenous insulin secretion. Restoration of some insulin secretion can therefore be convincing even in a single person with established T1D. Presumably, regenerated islets quickly come under autoimmune attack. Evidence of this was seen in the Phase 2 study of INGAP Peptide, in which some of the patient showed evidence of increased anti-islet activity \[[@r121]\]. These considerations suggest that even a minimally active islet regeneration agent can be used to facilitate the development of autoimmunity agents. A small factorial clinical study design incorporating as few as 24 established T1D patients treated with a regeneration agent and an autoimmunity agent could demonstrate the activity of the autoimmunity agent perhaps within 2 months, as opposed to the 2 years required to detect a modest effect in new onset patients.

In this sense, the co-development of immune and regeneration agents can be synergistic on multiple levels, starting with the pharmacological and extending to the commercial.

Conclusion
==========

People with T1D are not satisfied with the current technologies for managing their condition. They will welcome the advances in mechanical and biologic products that provide glucose-sensitive, autoregulated insulin delivery. However, these approaches will be expensive and demanding of their users. People with T1D will also welcome treatments that can be used to prevent or reduce the loss of insulin secretion in their family members, before or at onset of T1D. But, people living everyday with T1D will not be satisfied until they have a "practical cure of T1D" \[[@r137]\]. The quest for such a treatment has been among the most elusive in the annals of medicine. Substantial progress has been made and more progress is foreseeable. Accelerated progress will require sustained, concerted, and systematic efforts from academia, industry, government, and patients with T1D as well as their caregivers.
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![Progression of the type 1 diabetes disease process. This is a cellular autoimmune process occurring in individuals with a genetic predisposition to the disease, presumably triggered by some environmental factor. Humoral antibodies indicate that the disease process is underway, and there is then progressive impairment of -cell function manifested by progressive deterioration of glucose metabolism. The time frame is variable, so the x-axis is dimensionless. IAA, insulin autoantibody; ICA, islet cell antibody; IVGTT, intravenous glucose tolerance test; OGTT, oral glucose tolerance test (From Skyler JS and Ricordi C, 2011) \[[@r3]\].](CDR-13-300_F1){#F1}

![Potential time points for intervention to alter the type 1 diabetes disease process. Intervention may be attempted in the genetically at-risk to try to abrogate autoimmunity, in those with antibodies signifying that the disease process is underway, or in those with varying degrees of metabolic abnormalities, including at the time of clinical onset of type 1 diabetes (From Skyler JS and Ricordi C, 2011) \[[@r3]\]](CDR-13-300_F2){#F2}

###### 

Drugs Currently Approved for the Treatment of Type 1 Diabetes.

  ------------------------------------------------------------------------------------------------------------------------------
  **Compound**                 **Date First Approved**                           **Comments**
  ---------------------------- ------------------------------------------------- -----------------------------------------------
  Regular human insulin        1982 (FDA), 1984 (Europe); Bovine insulin: 1922   Peak insulin levels 2-4 hours after injection

  NPH insulin                  Marketed 1950                                     Long acting insulin

  Insulin aspart               1999 (EMA), 2000 (FDA)                            Rapid acting insulin analogue

  Insulin lispro               1996 (EMA), 1996 (FDA)                            Rapid acting insulin analogue

  Insulin glulisine            2004 (EMA), 2004 (FDA)                            Rapid acting insulin analogue

  Insulin glargine             2000 (EMA), 2000 (FDA)                            Long acting insulin analogue

  Insulin detemir              2004 (EMA), 2005 (FDA)                            Long acting insulin analogue

  Insulin degludec             2013 (EMA)\                                       Long acting insulin analogue
                               2015 (FDA)                                        

  Insulin glargine U300        2015 (EMA), 2015 (FDA)                            Long acting insulin analogue

  Afrezza^®^ inhaled insulin   2014 (FDA)                                        Rapid acting insulin for inhalation

  Pramlintide                  2005 (FDA)                                        Amylin analogue
  ------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of Clinical Development and Regulatory Expectations for Different Diabetes Therapies.

                                   **Cell Therapy for Severe T1D**                            **New Onset T1D Immune Therapy**         **New Insulin Analog**
  -------------------------------- ---------------------------------------------------------- ---------------------------------------- --------------------------------------------
  **Patient population**           Late T1D with disabling hypoglycemia                       All with T1D diagnosed within 3 months   Any T1D or T2D requiring insulin treatment
  **Study design**                 Single-arm open label                                      Placebo-controlled                       Active-controlled (insulin comparator)
  **Total N for submission**       200                                                        1000                                     4000
  **Primary endpoint**             Percent of subjects with HbA1c\<6.5% and no hypoglycemia   C-Peptide                                HbA1c Non-inferiority
  **Secondary endpoint**           Percent off insulin treatment at one year                  HbA1c, hypoglycemia, insulin dose        Hypoglycemia rates
  **Study duration to endpoint**   12 months                                                  24 months                                26-52 weeks
  **Long-term follow-up**          Important but informal                                     Strongly encouraged                      Only required for a subset
  **Requirement for CVOT**         No                                                         No                                       Only if a CV signal is detected
  **FDA Review Center**            CBER                                                       CDER                                     CDER

*Abbreviations:* T1D, Type 1 Diabetes; T2D, Type 2 Diabetes; CVOT, Cardiovascular Outcome Trial; CV, Cardiovascular; FDA, US Food and Drug Administration; CBER, Center for Biologics Evaluation and Research; CDER, Center for Drug Evaluation and Research
